Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry

Uribarri, Aitor; Núñez‐Gil, Iván J.; Alonso, Álvaro; Becerra-Muñoz, Víctor Manuel; Feltes, Gisela; Trabattoni, Daniela; Fernández-Rozas, Inmaculada; Viana-Llamas, María C; Pepe, Martino; Cerrato, Enrico; Capel-Astrua, Thamar; Romero, Rodolfo; Castro-Mejía, Alex F.; El‐Battrawy, Ibrahim; López-País, Javier; D’Ascenzo, Fabrizio; Fabregat-Andrés, Óscar; Bardajı́, Alfredo; Raposeiras‐Roubín, Sergio; Marín, Francisco; Fernández‐Ortíz, Antonio; Macaya, Carlos; Estrada, Vicente; Investigators, Hope Covid

doi:10.1007/s40620-020-00790-5

Cited by 103 publications

(124 citation statements)

References 22 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…While the study by Williamson et al [13] provides important information on the epidemiology of COVID-19 and is the first to convincingly demonstrate the importance of CKD as a risk factor for COVID-19 mortality, to our knowledge, this is the first study analyzing the combined effect of CKD and AKI in COVID-19 hospitalized patients in whom preexisting CKD has been specifically investigated on the basis of kidney function (eGFR and urinalysis) within the 180 days before COVID-19 diagnosis. Even when we estimated the prevalence of CKD based on the reported medical history, we observed a significantly higher prevalence of CKD (11.8%) as compared to that described in early reports in China (0.7%) [14] and in Europe (8.5%) [15] on a historical basis. This difference might be explained by the older age of our population and the high prevalence of multiple comorbidities, both well-established risk factors for chronic renal disease [16].…”

Section: Discussioncontrasting

confidence: 73%

“…With regard to the incidence of AKI among COVID-19 patients, it has been reported with great heterogeneity, mainly because of variable definition criteria and different baseline populations considered [15,17]. In early reports, AKI was described as a rare event [14], while in larger cohorts of patients from China and the U.S., its incidence varied from 5 to 36% [3,4,18].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy

et al. 2020

View full text Add to dashboard Cite

Background The prevalence of kidney involvement during SARS-CoV-2 infection has been reported to be high. Nevertheless, data are lacking about the determinants of acute kidney injury (AKI) and the combined effect of chronic kidney disease (CKD) and AKI in COVID-19 patients. Methods We collected data on patient demographics, comorbidities, chronic medications, vital signs, baseline laboratory test results and in-hospital treatment in patients with COVID-19 consecutively admitted to our Institution. Chronic kidney disease was defined as eGFR < 60 mL/min per 1.73 m2 or proteinuria at urinalysis within 180 days prior to hospital admission. AKI was defined according to KDIGO criteria. The primary and secondary outcomes were the development of AKI and death. Results Of 777 patients eligible for the study, acute kidney injury developed in 176 (22.6%). Of these, 79 (45%) showed an acute worsening of a preexisting CKD, and 21 (12%) required kidney replacement therapy. Independent associates of AKI were chronic kidney disease, C-reactive protein (CRP) and ventilation support. Among patients with acute kidney injury, 111 died (63%) and its occurrence increased the risk of death by 60% (HR 1.60 [95% IC 1.21–2.49] p = 0.002) independently of potential confounding factors including hypertension, preexisting kidney damage, and comorbidities. Patients with AKI showed a significantly higher rate of deaths attributed to bleeding compared to CKD and the whole population (7.5 vs 1.5 vs 3.5%, respectively). Conclusion Awareness of kidney function, both preexisting CKD and development of acute kidney injury, may help to identify those patients at increased risk of death.

show abstract

Section: Discussioncontrasting

confidence: 73%

Section: Discussionmentioning

confidence: 99%

Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Furthermore, the observation in this study was in support of the studies by Guan et al in 2020 which showed that presence of comorbidities such as hypertension, obesity, chronic lung disease, diabetes, and cardiovascular disease adversely affect and directly correlates with poor clinical outcome of patients with COVID-19 [25,26]. Similarly, this study was also analogous to other studies by Oyelade et al and Uribarri et al in 2020 which show that renal failure in patients with COVID-19 is associated with increase in severity and in-patient mortality [27,28].…”

Section: Discussionsupporting

confidence: 82%

Poor Prognostic Factors in Sickle Cell Disease Patients Infected with Covid-19 – Review of Literatures

Abiola¹,

Abdul²,

Muhammad³

2020

AJLM

View full text Add to dashboard Cite

Sickle cell disease (SCD) is the co-inheritance of HbS with other abnormal haemoglobin. COVID-19 is a severe acute respiratory distress syndrome caused by coronavirus 2 infections. The immunosuppression and chronic inflammatory states in patients with SCD predispose them to severe form of COVID-19. The few case studies on sickle cell disease patients infected with COVID-19 mostly discuss the pattern of clinical presentations and laboratory changes in patients with SCD infected with COVID-19. This review of literature assesses the prognostic indicators in sickle cell disease patients infected with COVID 19 in three major case series. Some presenting symptoms and signs, presence of comorbidities and certain laboratory parameters were compared with poor outcome of patients. Poor clinical outcomes of patients in this review included: 1. Duration of admission of ≥10 days, 2. A week or more of intensive care unit admission, 3. Death of patient despite intervention while on admission, and 4. Deterioration in the presenting comorbid clinical condition. The presenting symptoms and signs, presence of comorbidities and certain laboratory parameters associated with these poor clinical outcomes were considered as poor prognostic factors. The presence of comorbidities, markedly elevated pro-inflammatory markers such as leukocytosis, IL-6, C-reactive proteins, marked elevated D-Dimer and high serum creatinine are poor prognostic factors in sickle cell disease patients with COVID-19 infection.

show abstract

“…population, and renal failure may lead to more complications and higher in-hospital mortality. 24 Ischemic heart disease appeared equally prevalent in inpatients with COVID-19…”

Section: Sensitivity Analysismentioning

confidence: 99%

30-day mortality and morbidity in COVID-19 versus influenza: A population- based study

Nersesjan

Amiri

Christensen

et al. 2020

Preprint

View full text Add to dashboard Cite

Background As of July 2020, COVID-19 has caused 500,000 deaths worldwide. However, large-scale studies of COVID-19 mortality and new-onset comorbidity compared to influenza and individuals tested negative for COVID-19 are lacking. We aimed to investigate COVID-19 30-day mortality and newonset comorbidity compared to individuals with negative COVID-19 test results and individuals tested for influenza. Methods and findings This population-based cohort study utilized electronic health records covering roughly half (n=2,647,229) of Denmark's population, with nationwide linkage of microbiology test results and death records. All individuals ≥18 years tested for COVID-19 and individuals tested for influenza were followed from November 1, 2017 to June 30, 2020. The main outcome was 30-day mortality after a test for either COVID-19 or influenza. Secondary outcomes were major comorbidity diagnoses 30-days after the test for either COVID-19 or influenza. In total, 224,639 individuals were tested for COVID-19. Among inpatients positive for COVID-19, 356 of 1657 (21%) died within 30 days, which was a 3.0 to 3.1-fold increased 30-day mortality rate, when compared to influenza and COVID-19-negative inpatients (all p<0.001). For outpatients, 128 of 6,263 (2%) COVID-19-positive patients died within 30 days, which was a 5.5 to 6.9-fold increased mortality rate compared to influenza and COVID-19-negative patients, respectively (all p<0.001). Compared to hospitalized patients with influenza, new-onset ischemic stroke, diabetes and nephropathy occurred more frequently in inpatients with COVID-19 (all p<0.05). Conclusions In this population-based study comparing COVID-19 with influenza, COVID-19 was associated with increased rates of major systemic and vascular comorbidity and substantially higher mortality, which is likely even higher than the stated 3.0 to 5.5-fold increase owing to more extensive testing for COVID-19.

show abstract

Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry

Cited by 103 publications

References 22 publications

Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy

Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy

Poor Prognostic Factors in Sickle Cell Disease Patients Infected with Covid-19 – Review of Literatures

30-day mortality and morbidity in COVID-19 versus influenza: A population- based study

Contact Info

Product

Resources

About